XOMA Royalty Corporation (NASDAQ:XOMA) — Market Cap & Net Worth

$505.19 Million USD  · Rank #12562

Market Cap & Net Worth: XOMA Royalty Corporation (XOMA)

XOMA Royalty Corporation (NASDAQ:XOMA) has a market capitalization of $505.19 Million ($505.19 Million) as of May 23, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12562 globally and #2994 in its home market, demonstrating a -0.83% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying XOMA Royalty Corporation's stock price $41.65 by its total outstanding shares 12129405 (12.13 Million). Analyse XOMA Royalty Corporation (XOMA) cash conversion ratio to see how efficiently the company converts income to cash.

XOMA Royalty Corporation Market Cap History: 2015 to 2026

XOMA Royalty Corporation's market capitalization history from 2015 to 2026. Data shows growth from $322.64 Million to $505.19 Million (6.68% CAGR).

Index Memberships

XOMA Royalty Corporation is a constituent of 2 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NASDAQ Health Care
IXHC
$2.44 Trillion 0.02% #327 of 976
NASDAQ Composite
IXIC
$42.06 Trillion 0.00% #1206 of 3165

Weight: XOMA Royalty Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

XOMA Royalty Corporation Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how XOMA Royalty Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

6.18x

XOMA Royalty Corporation's market cap is 6.18 times its annual revenue

Industry average: 4918.66x Lower than industry average

Latest Price to Earnings (P/E) Ratio

10.17x

XOMA Royalty Corporation's market cap is 10.17 times its annual earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $51.19 Million $5.56 Million -$53.53 Million 9.20x N/A
2017 $431.81 Million $52.69 Million $14.60 Million 8.20x 29.58x
2018 $153.44 Million $5.30 Million -$13.34 Million 28.96x N/A
2019 $331.13 Million $18.37 Million -$1.98 Million 18.03x N/A
2020 $535.27 Million $29.39 Million $13.30 Million 18.22x 40.25x
2021 $252.90 Million $38.16 Million $15.80 Million 6.63x 16.01x
2022 $223.18 Million $6.03 Million -$17.10 Million 37.03x N/A
2023 $224.39 Million $4.76 Million -$40.83 Million 47.16x N/A
2024 $318.76 Million $28.49 Million -$13.82 Million 11.19x N/A
2025 $322.52 Million $52.15 Million $31.71 Million 6.18x 10.17x

Competitor Companies of XOMA by Market Capitalization

Companies near XOMA Royalty Corporation in the global market cap rankings as of May 23, 2026.

Key companies related to XOMA Royalty Corporation by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.28 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #417 globally with a market cap of $65.82 Billion USD.
  • argenx NV ADR (NASDAQ:ARGX): Ranked #579 globally with a market cap of $45.97 Billion USD.
  • UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #599 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#222 Vertex Pharmaceuticals Inc NASDAQ:VRTX $110.28 Billion $434.52
#417 Regeneron Pharmaceuticals Inc NASDAQ:REGN $65.82 Billion $638.88
#579 argenx NV ADR NASDAQ:ARGX $45.97 Billion $787.95
#599 UCB S.A. UNSP.ADR 1/2 F:UNC0 $44.84 Billion €120.00

XOMA Royalty Corporation Historical Marketcap From 2015 to 2026

Between 2015 and today, XOMA Royalty Corporation's market cap moved from $322.64 Million to $ 505.19 Million, with a yearly change of 6.68%.

Year Market Cap Change (%)
2026 $505.19 Million +56.64%
2025 $322.52 Million +1.18%
2024 $318.76 Million +42.05%
2023 $224.39 Million +0.54%
2022 $223.18 Million -11.75%
2021 $252.90 Million -52.75%
2020 $535.27 Million +61.65%
2019 $331.13 Million +115.81%
2018 $153.44 Million -64.47%
2017 $431.81 Million +743.60%
2016 $51.19 Million -84.14%
2015 $322.64 Million --

End of Day Market Cap According to Different Sources

On May 23rd, 2026 the market cap of XOMA Royalty Corporation was reported to be:

Source Market Cap
Yahoo Finance $505.19 Million USD
MoneyControl $505.19 Million USD
MarketWatch $505.19 Million USD
marketcap.company $505.19 Million USD
Reuters $505.19 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About XOMA Royalty Corporation

NASDAQ:XOMA USA Biotechnology
Market Cap
$505.19 Million
Market Cap Rank
#12562 Global
#2994 in USA
Share Price
$41.65
Change (1 day)
-0.41%
52-Week Range
$22.89 - $42.00
All Time High
$45.61
About

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with co… Read more